vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Apollo Commercial Real Estate Finance, Inc. (ARI). Click either name above to swap in a different company.
Apollo Commercial Real Estate Finance, Inc. is the larger business by last-quarter revenue ($73.3M vs $44.9M, roughly 1.6× AbCellera Biologics Inc.). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs -19.9%, a 59.8% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 4.0%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -4.6%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.
ABCL vs ARI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $73.3M |
| Net Profit | $-8.9M | $29.2M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | 39.7% |
| Net Margin | -19.9% | 39.9% |
| Revenue YoY | 788.4% | 4.0% |
| Net Profit YoY | 73.9% | -28.2% |
| EPS (diluted) | $-0.03 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $73.3M | ||
| Q3 25 | $9.0M | $61.6M | ||
| Q2 25 | $17.1M | $70.9M | ||
| Q1 25 | $4.2M | $65.8M | ||
| Q4 24 | $5.0M | $70.5M | ||
| Q3 24 | $6.5M | $71.6M | ||
| Q2 24 | $7.3M | $81.1M | ||
| Q1 24 | $10.0M | $80.5M |
| Q4 25 | $-8.9M | $29.2M | ||
| Q3 25 | $-57.1M | $50.8M | ||
| Q2 25 | $-34.7M | $20.7M | ||
| Q1 25 | $-45.6M | $26.0M | ||
| Q4 24 | — | $40.7M | ||
| Q3 24 | $-51.1M | $-91.5M | ||
| Q2 24 | $-36.9M | $35.8M | ||
| Q1 24 | $-40.6M | $-104.5M |
| Q4 25 | -63.7% | 39.7% | ||
| Q3 25 | -851.8% | 82.8% | ||
| Q2 25 | -290.2% | 29.4% | ||
| Q1 25 | -1479.6% | 39.7% | ||
| Q4 24 | — | 57.9% | ||
| Q3 24 | -1439.4% | -127.8% | ||
| Q2 24 | -1276.2% | 44.2% | ||
| Q1 24 | -551.5% | -129.6% |
| Q4 25 | -19.9% | 39.9% | ||
| Q3 25 | -637.8% | 82.4% | ||
| Q2 25 | -203.3% | 29.3% | ||
| Q1 25 | -1077.2% | 39.5% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | -785.4% | -127.9% | ||
| Q2 24 | -504.3% | 44.1% | ||
| Q1 24 | -408.0% | -129.8% |
| Q4 25 | $-0.03 | $0.19 | ||
| Q3 25 | $-0.19 | $0.34 | ||
| Q2 25 | $-0.12 | $0.12 | ||
| Q1 25 | $-0.15 | $0.16 | ||
| Q4 24 | — | $0.25 | ||
| Q3 24 | $-0.17 | $-0.69 | ||
| Q2 24 | $-0.13 | $0.23 | ||
| Q1 24 | $-0.14 | $-0.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $139.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $1.9B |
| Total Assets | $1.4B | $9.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $139.8M | ||
| Q3 25 | $83.2M | $245.9M | ||
| Q2 25 | $92.4M | $177.6M | ||
| Q1 25 | $159.3M | $166.4M | ||
| Q4 24 | $156.3M | $317.4M | ||
| Q3 24 | $126.6M | $194.3M | ||
| Q2 24 | $148.3M | $174.7M | ||
| Q1 24 | $123.6M | $161.2M |
| Q4 25 | $966.9M | $1.9B | ||
| Q3 25 | $964.0M | $1.9B | ||
| Q2 25 | $1.0B | $1.8B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.1B | $1.9B | ||
| Q3 24 | $1.1B | $1.9B | ||
| Q2 24 | $1.1B | $2.0B | ||
| Q1 24 | $1.1B | $2.0B |
| Q4 25 | $1.4B | $9.9B | ||
| Q3 25 | $1.4B | $9.5B | ||
| Q2 25 | $1.4B | $9.8B | ||
| Q1 25 | $1.3B | $8.8B | ||
| Q4 24 | $1.4B | $8.4B | ||
| Q3 24 | $1.4B | $9.1B | ||
| Q2 24 | $1.4B | $9.3B | ||
| Q1 24 | $1.5B | $9.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $142.5M |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | 4.88× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $142.5M | ||
| Q3 25 | $-52.6M | $31.7M | ||
| Q2 25 | $-32.4M | $63.2M | ||
| Q1 25 | $-11.6M | $39.3M | ||
| Q4 24 | $-108.6M | $200.3M | ||
| Q3 24 | $-28.9M | $47.2M | ||
| Q2 24 | $-30.0M | $50.2M | ||
| Q1 24 | $-41.7M | $52.8M |
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-187.0M | — | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | — | ||
| Q1 24 | $-65.8M | — |
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -3702.8% | — | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | — | ||
| Q1 24 | -661.5% | — |
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 1552.7% | — | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | — | ||
| Q1 24 | 242.5% | — |
| Q4 25 | — | 4.88× | ||
| Q3 25 | — | 0.62× | ||
| Q2 25 | — | 3.05× | ||
| Q1 25 | — | 1.51× | ||
| Q4 24 | — | 4.93× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.40× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
